Cosmos Health Q3 EPS Estimate Decreased by Zacks Research

Cosmos Health Inc. (NASDAQ:COSM) – Equities research analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Cosmos Health in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst B. Sorensen now forecasts that the company will earn ($0.05) per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for Cosmos Health’s current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Cosmos Health’s Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.21) EPS.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings results on Tuesday, August 18th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.11). The firm had revenue of $19.32 million during the quarter, compared to the consensus estimate of $18.99 million. Cosmos Health had a negative net margin of 33.08% and a negative return on equity of 56.88%.

Separately, Weiss Ratings upgraded Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Cosmos Health Stock Up 8.8%

NASDAQ:COSM opened at $0.21 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.92 and a current ratio of 1.05. The company has a market cap of $12.61 million, a PE ratio of -0.33 and a beta of 4.80. Cosmos Health has a 52-week low of $0.16 and a 52-week high of $1.32. The stock has a 50-day simple moving average of $0.22 and a 200 day simple moving average of $0.30.

Insider Activity

In related news, CEO Grigorios Siokas bought 349,825 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were acquired at an average price of $0.20 per share, with a total value of $69,965.00. Following the completion of the transaction, the chief executive officer owned 14,597,917 shares in the company, valued at $2,919,583.40. The trade was a 2.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Georgios Terzis bought 168,135 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $0.25 per share, for a total transaction of $42,033.75. Following the acquisition, the chief financial officer directly owned 2,235,398 shares of the company’s stock, valued at $558,849.50. This represents a 8.13% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 2,204,138 shares of company stock worth $457,137 over the last three months. Insiders own 26.15% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Cosmos Health in the 2nd quarter valued at approximately $49,000. XTX Topco Ltd increased its holdings in Cosmos Health by 52.1% during the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after buying an additional 34,117 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Cosmos Health by 16.7% during the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock worth $124,000 after buying an additional 55,925 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in Cosmos Health by 133.1% during the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares in the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.